SAN DIEGO (AP) — SAN DIEGO (AP) — Kura Oncology Inc. (KURA) on Wednesday reported a loss of $19.2 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of 22 cents.
The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 63 cents per share.
The biopharmaceutical company posted revenue of $53.9 million in the period, which fell short of Street forecasts. Three analysts surveyed by Zacks expected $229.2 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KURA at https://www.zacks.com/ap/KURA
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。